Affordable inactivated poliovirus vaccine: Strategies and progress

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S459-S464

  Okayasu, Hiromasa ^a   Sutter, Roland W ^a   Jafari, Hamid S ^a   Takane, Marina ^a   Aylward, R Bruce ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

adjuvant; affordability; further attenuated poliovirus strains; inactivated poliovirus vaccine; intradermal administration; production optimization; schedule reduction

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOLOGICAL ADJUVANT; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ALPHAVIRUS REPLICON PARTICLE; ARTICLE; BIOTECHNOLOGICAL PROCEDURES; COST CONTROL; DEVELOPING COUNTRY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG USE; ERADICATION THERAPY; HEALTH CARE POLICY; HUMAN; IMMUNOGENICITY; INTRADERMAL DELIVERY SYSTEM; LARGE SCALE PRODUCTION; LOWEST INCOME GROUP; MICRONEEDLE PATCH; NONHUMAN; PACKAGING CELL APPROACH; POLIOMYELITIS VIRUS; PROCESS OPTIMIZATION; REDUCING NUMBER OF VACCINE DOSE; VACCINATION; VACCINE PRODUCTION; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS STRAIN; DISEASE ERADICATION; DRUG DEVELOPMENT; ECONOMICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; POLIOMYELITIS; PROCEDURES; WORLD HEALTH ORGANIZATION;

DEVELOPING COUNTRIES; DISEASE ERADICATION; DRUG DISCOVERY; HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; WORLD HEALTH ORGANIZATION;

EID: 84910601697     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu128     Document Type: Article

References (49)

1. Global Polio Eradication Initiative. Polio this week. 21 May 2014. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx. Accessed 22 May 2014.
2. UNICEF supply division. Current OPV supply and outlook. http://www.unicef.org/supply/files/Oral-polio-vaccine-update.pdf. Accessed 20 February 2014.
3. World Health Organization. Risk assessment: frequency and burden of VAPP, cVDPV and iVDPV. In: Rep Interim Meet Tech Consult Group TCG Glob Erad Polio. Geneva: World Health Organization, 2003:17-20. http://whqlibdoc.who.int/hq/2003/WHO-V&B-03.04.pdf. Accessed 20 February 2014.
4. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587-635.
5. World Health Organizatio n. Agenda item 11.2 Poliomyelitis: mechanism for management of potential risks to eradication. In: Seventh plenary meeting. Sixty-First World Health Assembly. Geneva: World Health Organization. http://www.polioeradication.org/content/general/WHA61-Resolution-English.pdf. Accessed 20 February 2014.
6. Global Polio Eradication Initiative. Strategic plan 2010-2012. http://www.polioeradication.org/Portals/0/Document/StrategicPlan/StratPlan2010-2012-ENG.pdf. Accessed 20 February 2014.
7. Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx. Accessed 20 February 2014.
8. Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010; 362:2351-9.
9. Resik S, Tejeda A, Lago PM, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010; 201:1344-52.
10. Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010; 376:1682-8.
11. Centers for Disease Control and Prevention (CDC). Apparent global interruption of wild poliovirus type 2 transmission.MMWRMorb Mortal Wkly Rep 2001; 50:222-4.
12. Aylward B, Yamada T. The polio endgame. N Engl J Med 2011; 364:2273-5.
13. UNICEF supply division. Current IPV supply, recent tender results and outlook for the future. http://www.unicef.org/supply/files/IPV-Supply-Status-UNICEF-SD-v6.pdf. Accessed 20 February 2014.
14. World Health Organization. Agenda item 13.10. Poliomyelitis: intensification of the global eradication initiative. In: Tenth plenary meeting, Sixty-Fifth World health Assembly. Geneva: World Health Organization, 2012. http://apps .who.int/gb/ebwha/pdf-files/EB132/B132-17-en.pdf. Accessed 20 February 2014.
15. Meeting of the Strategic Advisory Group of Experts on immunization, November 2013-conclusions and recommendations. Wkly Epidemiol Rec 2014; 89:1-20.
16. Poliovirus Vaccine and Vaccine-Derived Polioviruses. N Engl J Med 2010; 363:1870-1.
17. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010; 85:213-28.
18. Estívariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013; 3:309-15.
19. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368:416-24.
20. Salk JE. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc 1953; 151:1081-98.
21. Salk JE. Recent studies on immunization against poliomyelitis. Pediatrics 1953; 12:471-82.
22. Samuel BU, Cherian T, Sridharan G, Mukundan P, John TJ. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 1991; 338:343-4.
23. Samuel BU, Cherian T, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine 1992; 10:135.
24. Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to fractional doses of intr adermally administered inactivated poliovirus vaccine. Vaccine 1998; 16:928-31.
25. Cadorna-Carlos J, Vidor E, BonnetM-C. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis 2012; 16:e110-6.
26. Meeting of the Strategic Advisory Group of Experts on immunization, April 2012-conclusions and recommendations. Wkly Epidemiol Rec 2012; 87:201-16.
27. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454-9.
28. Hung IFN, Levin Y, To KKW. Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine 2012; 30:2707-8.
29. Hung IFN, Levin Y, To KKW, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 2012; 30:6427-35.
30. Ansaldi F, Durando P, Icardi G. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther 2011; 11:415-27.
31. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16:915-20.
32. Edens C, Collins ML, Ayers J, Rota PA, Prausnitz MR. Measles vaccination using a microneedle patch. Vaccine 2013; 31:3403-9.
33. Moon S, Wang Y, Edens C, Gentsch JR, Prausnitz MR, Jiang B. Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. Vaccine 2013; 31:3396-402.
34. Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 2006; 193:598-600.
35. Yang C, Shi H, Zhou J, Liang Y, Xu H. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 2009; 27:6558-63.
36. Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-inwater emulsions. Vaccine 2011; 29:644-9.
37. Westdijk J, Koedam P, Barro M, et al. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 2013; 31:1298-304.
38. Bakker WAM, Thomassen YE, van' t Oever AG, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011; 29:7188-96.
39. Bakker WAM. Sabin-IPV development, clinical trials & optimization. 2012. http://www.who.int/immunization-standards/vaccine-quality/bakker-sabinipv-dev-optimization-oct12.pdf. Accessed 20 February 2014.
40. Tonkin DR, Jorq uera P, Todd T, Beard CW, Johnston RE, Barro M. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 2010; 28:3238-46.
41. Che Y-C, Jiang L, Shao C-W. Feasibility study of using Sabin-IPV immunization in post-eradication era in China. Zhongguo Yi Miao He Mian Yi 2010; 16:72-5.
42. Shimizu B, Abe S, Yamamoto H, et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biol J Int Assoc Biol Stand 2006; 34:151-4.
43. Shimizu H. Poliovirus vaccine. Uirusu 2012; 62:57-65.
44. Verdijk P, Rots NY, Bakker WAM. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 2011; 10:635-44.
45. Rolli G Progress toward a low COGs PER.C6 based IPV Eleventh WHO/UNICEF consultation with OPV/IPV manufacturers and NRAs Geneva World Health Organization 2012. http://www.who.int/immunization-standards/vaccine-quality/rolli-crucell-progress-ipv-oct12.pdf?ua=1. Accessed 20 February 2014.
46. Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis 2008; 47:1587-92.
47. S tony Brook University. Stable packaging cell lines for the same and efficient manufacture of vaccines against polio and other viruses. http://www.stonybrook.edu/research/otlir/technologies/Therapeutics/R-8166.pdf. Accessed 20 February 2014.
48. Ma B, Maraj B, Tran NP, et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2012; 17:469-92.
49. Global Polio Eradication Initiative. Polio eradication and endgame strategic plan 2013-2018, 2013. http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP-EN-A4.pdf. Accessed 20 February 20 14.